Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

6.3%

2 terminated out of 32 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

150%

6 of 4 completed with results

Key Signals

6 with results67% success

Data Visualizations

Phase Distribution

26Total
Not Applicable (4)
Early P 1 (6)
P 1 (11)
P 2 (4)
P 3 (1)

Trial Status

Active Not Recruiting12
Recruiting10
Withdrawn4
Completed4
Terminated2

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (32)

Showing 20 of 20 trials
NCT04491942Phase 1Active Not Recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

NCT03939481Active Not Recruiting

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

NCT05039801Phase 1Recruiting

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT04514484Phase 1Active Not Recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT07259304Recruiting

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

NCT04550494Phase 2Recruiting

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04314401Active Not Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

NCT06630325Phase 2Terminated

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

NCT04095364Phase 3Active Not Recruiting

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03943173Early Phase 1Active Not Recruiting

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

NCT07144826Early Phase 1Recruiting

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

NCT05415709Early Phase 1Recruiting

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

NCT07226102Not ApplicableWithdrawn

Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer

NCT03707574Completed

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

NCT05786456Not ApplicableActive Not Recruiting

e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study

NCT05092373Phase 1Recruiting

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

NCT04673448Phase 1Active Not Recruiting

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

NCT06855706Not ApplicableRecruiting

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study

NCT05276973Phase 1Active Not Recruiting

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

NCT04501913Completed

Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes

Scroll to load more

Research Network

Activity Timeline